Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Analysis of Gene Expression Following Treatment with BTK and PI3Kδ Inhibitors in Chronic Lymphocytic Leukemia Reveals CXCR4 as a Potential Target for Combination Therapy

  • By

  • Gabriela Mladonicka Pavlasova

  • Veronika Sandova

  • Laura Ondrisova

  • Vaclav Seda

  • Petra Pavelkova

  • Daniel Filip

  • Krystof Hlavac

  • Josef Vecera

  • Sarka Pospisilova

  • Anna Panovska

  • Stacey M. Fernandes

  • Michael Doubek

  • Jennifer R. Brown

  • Marek Mraz

  • September 25, 2026

Share

Original Source(s)

Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy

  • by Gabriela Mladonicka Pavlasova, Veronika Sandova, Laura Ondrisova, Vaclav Seda, Petra Pavelkova, Daniel Filip, Krystof Hlavac, Josef Vecera, Sarka Pospisilova, Anna Panovska, Stacey M. Fernandes, Michael Doubek, Jennifer R. Brown, Marek Mraz

  • September 25, 2026

Related Content

Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer

Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?